Use of tocilizumab in patients with SARS-CoV-2 at Hospital Nacional Dos de Mayo – Lima, 2020
DOI:
https://doi.org/10.15381/ci.v25i1.23472Keywords:
Tocilizumab, SARS-CoV-2Abstract
Objective: To determine the characteristics of the use of tocilizumab (TCZ) in patients hospitalized for SARS-CoV-2, at the Dos de Mayo National Hospital in the months of April to September 2020. Methodology: Descriptive study of transverse cut. The sample consisted of 141 patients infected with SARS-CoV-2, from whom complete information on registered medical prescriptions and medical records was collected. Results: Age was 58.9 ± 11.2 years, 78% were male, weight was 79.6 ± 12.0 Kg, showing that 41.8% and 44.2% were overweight and obese, respectively. In addition, 99.3% of patients showed respiratory rate greater than 22 breaths/minute, 97.2% had blood pressure of less than 100 mmHg and 99.3% had oxygen saturation (SpO2) less than 85% and the common inflammatory markers were PCR>100 mg/dL (75.2%), Ferritin>700 ng/mL (59.6%), D-Dimer> 1000 µg/mL (77.3%), DHL>350 U/L (58.9%) and IL-6>40 pg/mL (48.9%). On the other hand, a total of 275 TCZ units were administered, with a total cost of S/ 703 872,40. The average hospital stay was 17,8 ± 13,6 days, observing that 55.3% died. Conclusion: the main characteristic of the use of TCZ at the Dos de Mayo National Hospital was the prescription of this monoclonal antibody in patients hospitalized with severe COVID-19, a total cost of S/ 703 872,40 and no improvement in survival rates mortality.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Katya Cuba Pérez, Martín Condorhuamán Figueroa
This work is licensed under a Creative Commons Attribution 4.0 International License.
LOS AUTORES RETIENEN SUS DERECHOS:
- Los autores retienen sus derechos de marca y patente, y tambien sobre cualquier proceso o procedimiento descrito en el artículo.
- Los autores retienen el derecho de compartir, copiar, distribuir, ejecutar y comunicar públicamente el articulo publicado en la Revista Ciencia e Investigación (por ejemplo, colocarlo en un repositorio institucional o publicarlo en un libro), con un reconocimiento de su publicación inicial en la Revista Ciencia e Investigación.
- Los autores retienen el derecho a hacer una posterior publicación de su trabajo, de utilizar el artículo o cualquier parte de aquel (por ejemplo: una compilación de sus trabajos, notas para conferencias, tesis, o para un libro), siempre que indiquen la fuente de publicación (autores del trabajo, revista, volumen, numero y fecha).
